ASH 2010 News Coverage

ASH 2010

Carfilzomib Has Potential to Offer Substantial Clinical Benefit to Patients With Relapsed/Refractory Multiple Myeloma; Subset Analysis Finds No Impact of Baseline Peripheral Neuropathy on Efficacy

Treatment with single-agent carfilzomib achieved durable responses in patients with relapsed/refractory multiple myeloma whose disease had relapsed after they received all available therapies (including bortezomib and immunomodulatory agents), suggesting that this agent has the potential to offer substantial clinical benefit. The data was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

Therapeutic Potential of Bosutinib Observed in Patients With Chronic-Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy With Dasatinib or Nilotinib

Bosutinib has therapeutic potential in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic-phase (CP) chronic myeloid leukemia (CML) with resistance to—or, particularly, intolerance to—other second-generation tyrosine kinase inhibitor (TKI) therapies, results of an open-label, phase 1/2 study presented at the 52nd American Society of Hematology Annual Meeting and Exposition has found.

Outpatient Anticoagulant Treatment Effective, Safe for Patients With Pulmonary Embolism Selected Using Hestia Criteria

Patients with pulmonary embolism (PE) are initially treated in the hospital with low molecular weight heparin (LMWH). Using Hestia criteria, however, they may be selected and safely treated as outpatients, results of a clinical study presented at the 52nd American Society of Hematology Annual Meeting and Exposition have found.

Ibritumomab Tiuxetan Consolidation Following CHOP + Rituximab Improves Outcomes in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)

Consolidation with yttrium-90 ibritumomab tiuxetan following dose-dense cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (CHOP-R) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) converted partial remissions (PR) to complete remissions (CR) and maintained durable responses with acceptable toxicity, according to a study presented at the 52nd American Society of Hematology Annual Meeting and Exposition..

In Patients With Newly Diagnosed or Previously Treated Follicular Lymphoma Responding to Induction Therapy, Maintenance Rituximab Is Effective

Updated results from the phase 3b MAXIMA study provides additional support for utilizing rituximab maintenance every 2 months for 2 years following rituximab-containing induction therapy for patients with newly diagnosed or previously treated follicular lymphoma (FL). The data was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

Intravenous Verses Oral Busulfan With Cyclophosphamide for Allogeneic Hematopoietic Progenitor Cell Transplant Conditioning for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

A study by Ronald Sobecks, MD, and colleagues at the Cleveland Clinic in Cleveland, Ohio, has been found that using IV busulfan (Bu) instead of oral Bu reduces variability in drug exposure and potentially improves safety. The study was presented at the 52nd American Society of Hematology Meeting and Exposition.

Nilotinib Safe, Effective in Patients With Chronic-Phase Chronic Myeloid Leukemia and Type 2 Diabetes

Hyperglycemia occurring during front-line treatment with nilotinib was usually mild, transient, manageable, and did not lead to treatment discontinuation in patients with chronic-phase chronic myeloid leukemia (CML-CP) with or without preexisting type 2 diabetes, according to a study presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

Bortezomib + Rituximab Shows Benefit in Patients With Relapsed, Rituximab-Naive or -Sensitive Follicular Lymphoma vs Rituximab Alone

In patients with relapsed follicular lymphoma (FL), the addition of weekly bortezomib (Vc) to rituximab (R) was associated with statistically significant improvements in progression-free survival (PFS), response rate, and time to next anti-lymphoma treatment, results of a randomized phase 3 trial presented at the 52nd American Society of Hematology Annual Meeting and Exposition have found.

Bendamustine Plus Rituximab Provides Superior Progression-Free Survival Benefit to Patients With Relapsed Follicular, Indolent, or Mantle Cell Lymphomas vs Fludarabine Plus Rituximab

Bendamustine plus rituximab (B-R) demonstrated a superior progression-free survival benefit in patients with relapsed follicular, indolent, or mantle cell lymphomas when compared with fludarabine plus rituximab (F-R), final results of a randomized phase 3 study presented at the 52nd American Society of Hematology Annual Meeting and Exposition have confirmed.